Clinical trial NCT02132312: A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
Official title: A Randomized, Double-Masked, Parallel-Group, Phenylephrine-Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Unilateral Cataract Extraction
Congenital Cataract
Keywords: Cataract
Lens replacement
pediatric
Lead sponsor: Omeros Corporation
Sponsor class: INDUSTRY
First posted: 2014-05-07
Enrollment: 78
Sex: ALL
Minimum age (years): 1
Maximum age (years): 47
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of OMS302 compared to phenylephrine when administered in irrigation solution during cataract extraction on intraoperative pupil diameter, acute postoperative pain, and safety in children birth through 3 years.

Detailed description: This study is a randomized, parallel-group, double-masked, phenylephrine-controlled study of OMS302 in young children ages birth through three years undergoing unilateral cataract extraction with or without lens replacement. Administration of test irrigation solutions will take place in a double-masked fashion.

Intraoperative pupil size will be determined by measurement of pupil diameter from still photos captured from video recordings of the procedure. Pupil diameter measurements will be performed immediately prior to the initial incision and at one-minute intervals until the end of the procedure (wound closure). Pain will be assessed by the Alder Hey Triage Pain Score.

Eligibility criteria: Inclusion Criteria:

1. Are 0 through three years of age at the time of surgery.
2. Are to undergo unilateral primary cataract extraction with or without lens replacement.
3. Have informed consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization provided by a parent or legal guardian in accordance with local regulations and governing IRB/IEC requirements prior to any procedures or evaluations performed specifically for the sole purpose of this study.
4. A parent or legal guardian has indicated that they understand and are able, willing, and likely to fully comply with study procedures and restrictions.

Exclusion Criteria:

1. Corneal diameter less than nine millimeters in the study eye.
2. Hypersensitivity to phenylephrine, ketorolac, or other NSAIDs, including aspirin, or latex.
3. Surgeon's expectation that the protocol-specified mydriatic regimen will not be adequate to perform the procedure and that additional mydriatic treatment (pharmacological or mechanical) will be required.
4. Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the Investigator.
5. Presence of active or suspected viral, bacterial, or fungal disease in the study eye.
6. Use of any topical medication in the study eye within seven days prior to surgery, except for medications needed to examine the eye or prepare for surgery.
7. Have a post-traumatic cataract.
8. History of uveitis or evidence of past uveitis such as synechiae or keratic precipitates in the study eye.
9. Have an ocular neoplasm in the study eye.
10. Have a clinically significant infection.
11. Have suspected permanent or low vision in the fellow non-study eye, unless caused by a cataract. The study eye must not be the subject's only good eye.
12. Use of systemic corticosteroids or NSAIDs in the seven days prior to surgery.
13. Have a history of clinically significant corticosteroid-induced intraocular pressure increase.
14. Use of any medication for ocular hypertension or glaucoma in the study eye.
15. Use of monoamine oxidase inhibitors for 21 days preoperatively.
16. Prior participation in a clinical study of OMS302.
17. Participating in any investigational drug or device trial within the 30 days prior to the day of surgery.
18. History of intraocular non-laser surgery in the study eye within the three months prior to the day of surgery, or intraocular laser surgery in the study eye within 30 days prior to the day of surgery.
19. Presence of any condition that the Investigator believes would put the subject at risk or confound the interpretation of the study data.
20. Be a member of the immediate family of the Investigator or employees of the investigative site. Immediate family is defined as the Investigator's or employees' natural or legally adopted child (including a stepchild living in the Investigator's household), or grandchild.

Primary outcomes:
measure: Intraoperative Pupil Diameter
timeFrame: From surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure), the mean time of surgery duration is 35.46 minutes with a standard deviation of 19.98.
measure: Acute Postoperative Pain
timeFrame: 24 hours
measure: Safety as Measured by Treatment-emergent Adverse Events, the Number of Affected Patients/at Risk (%) and the Number of Events.
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
state: California
city: Atlanta
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Indianapolis
country: United States
state: Indiana
city: Kansas City
country: United States
state: Kansas
city: Boston
country: United States
state: Massachusetts
city: Detroit
country: United States
state: Michigan
city: Charleston
country: United States
state: North Carolina
city: Nashville
country: United States
state: Tennessee
city: Dallas
country: United States
state: Texas
city: Madison
country: United States
state: Wisconsin
Study officials:
affiliation: Omeros Corporation
name: Steve Whitaker, MD
role: STUDY_DIRECTOR
References:
citation: Wilson ME, Trivedi RH, Plager DA. Safety and efficacy data supporting U.S. FDA approval of intracameral phenylephrine and ketorolac 1.0%/0.3% for pediatric cataract surgery: clinical safety and pupil and pain management. J Cataract Refract Surg. 2020 Jun;46(6):873-878. doi: 10.1097/j.jcrs.0000000000000194.